Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.
Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.
Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.
Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.
For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.
Personalis, Inc. (Nasdaq: PSNL) announced the appointment of Susan Moriconi as Vice President of People and Chief Human Resources Officer. With over 20 years of experience, Moriconi previously served at Omnicell, where she significantly scaled the workforce and helped increase revenues. Her leadership is expected to enhance Personalis' culture and support its growth in the life sciences sector. CEO John West expressed confidence in her ability to foster an inclusive and high-performing environment.
Personalis, Inc. (Nasdaq: PSNL) announced its participation in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference scheduled for February 18, 2021, at 12:00 p.m. ET. As a leader in cancer genomics and population sequencing, Personalis provides comprehensive molecular data about cancer and immune responses. The company also supports the U.S. Department of Veterans Affairs Million Veterans Program and offers the innovative ImmunoID NeXT Platform to aid biopharmaceutical customers in understanding genetic and immune system data from single samples.
Personalis, Inc. (Nasdaq: PSNL) announced a public offering of 3,950,000 shares at $38.00 each, aiming for gross proceeds of $150.1 million before expenses. The offering includes a 30-day underwriter option for an additional 592,500 shares. Morgan Stanley, BofA Securities, Citigroup, and Cowen are the joint book-running managers. The offering is backed by a shelf registration statement filed with the SEC. Personalis is recognized for its role in advanced genomics, particularly in cancer sequencing and partnering with the U.S. Department of Veterans Affairs.
Personalis, Inc. (Nasdaq: PSNL) has initiated a public offering of $150 million in common stock, with a potential additional $22.5 million available through underwriter options. This move is contingent on market conditions, and the completion date is uncertain. The offering is supported by major financial institutions including Morgan Stanley and BofA Securities. A registration statement for the shares was previously filed with the SEC. Investors are cautioned about the risks associated with the offering, including market unpredictability and regulatory compliance.
Personalis, Inc. (Nasdaq: PSNL) announced preliminary revenue for Q4 and full year 2020, estimating $20.2 million for Q4, an 11% increase from $18.2 million in Q4 2019. Full year revenue reached $78.6 million, up 21% from $65.2 million in 2019. Key highlights include a 73% increase in biopharma revenue to $7.6 million, although revenue from the VA Million Veterans Program fell 9% to $12.6 million. Cash reserves were estimated at $203 million as of December 31, 2020.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, announced its participation in the 23rd Annual Needham Virtual Growth Conference on January 13, 2021, at 2:45 p.m. Eastern Time. The company specializes in population sequencing and oncology, offering advanced molecular data to improve cancer treatment. Its ImmunoID NeXT Platform analyzes approximately 20,000 human genes and immune responses from a single tissue sample, supporting biopharmaceutical development. Personalis is recognized for its extensive sequencing operations and is the exclusive sequencing provider for the VA MVP.
Personalis, Inc. (Nasdaq: PSNL) has launched its innovative Neoantigen Presentation Score (NEOPS), which enhances cancer therapy predictions by integrating tumor neoantigen analysis with immune evasion mechanisms. NEOPS leverages the SHERPA™ tool and the Personalis NeXT Platform™ to improve patient stratification for immunotherapy responses. Data from an AACR meeting showcased NEOPS's superior predictive capabilities over traditional metrics like tumor mutational burden in late-stage melanoma patients. This development positions NEOPS as a vital tool for future clinical trials.
Personalis, Inc. (Nasdaq: PSNL) has launched its proprietary SHERPA tool, a machine learning algorithm designed for identifying cancer neoantigens. Integrated into the Personalis® NeXT Platform™, SHERPA is set to enhance the development of novel neoantigen-based diagnostic biomarkers, such as the Neoantigen Presentation Score (NEOPS™). Data from the SITC Annual Meeting indicates SHERPA exceeds traditional neoantigen prediction methods. The tool is also being utilized by Sarepta Therapeutics for precision genetic therapeutics, highlighting its versatility beyond oncology.
Personalis, Inc. (Nasdaq: PSNL) announced its upcoming presentation of clinical data for the NeXT DxTM test at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster, titled “An exome and transcriptome based NeXT DxTM test enables therapy selection for cancer patients,” will take place on Nov 17th between 1-2pm EST. The NeXT Dx test provides a diagnostic report on genomic alterations in 247 cancer-related genes and offers therapy recommendations, clinical trial matching, and biomarker results.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
What does Personalis, Inc. specialize in?
What are Personalis' main products?
Who can benefit from Personalis' services?
What technologies does Personalis use?
What is the mission of Personalis, Inc.?
How does Personalis support cancer research?
What recent achievements has Personalis made?
What sets Personalis apart from other genomic companies?
Why is genome sequencing important in medical research?
How can I stay updated on Personalis' latest news?
